GOG258 shows no difference in PFS or OS with chemotherapy vs. chemoRT followed by chemo, with more toxicity in the RT arm. In this trial, vaginal brachytherapy was not allowed in the chemotherapy alone arm; however, this is included in the NCCN guidelines as an option.